Clinical pharmacology of antiarrhythmic drugs: a review and overview, part Ii
Singh, B.N.; Cho, Y.W.; Kuemmerle, H.P.
International Journal of Clinical Pharmacology Therapy and Toxicology 19(5): 185-199
1981
ISSN/ISBN: 0174-4879 PMID: 6788721 Document Number: 179421
Document emailed within 1 workday
Related Documents
Roden, D.M. 1985: Antiarrhythmic drugs. Clinical pharmacology of the old and the new agents Postgraduate Medicine 78(4): 28-37Ernest, K. 1975: Pharmacology of new ethylenediamine derivatives (ROM-126, ROM-131, MK-142) with antiarrhythmic action. Part II. Antiarrhythmic properties, the influence on heart and some hemodynamic parameters Polish Journal of Pharmacology and Pharmacy 27(4): 381-398
Follath, F. 1991: Clinical pharmacology of antiarrhythmic drugs: variability of metabolism and dose requirements Journal of Cardiovascular Pharmacology 17(Suppl 6): S74-S76
Caillard, C.G.; Louis, J.C. 1980: Assessment of antiarrhythmic drugs in experimental pharmacology Methods and Findings in Experimental and Clinical Pharmacology 2(5): 223-252
Orszulak-Michalak, D. 1995: The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part II. N-acetylprocainamide Acta Poloniae Pharmaceutica 52(2): 147-151
Orszulak-Michalak, D. 1996: The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part V. Verapamil Acta Poloniae Pharmaceutica 53(1): 57-61
Orszulak-Michalak, D. 1995: The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part IV. Lidocaine Acta Poloniae Pharmaceutica 52(4): 315-319
Orszulak-Michalak, D. 1995: The influence of selected general anesthetics on pharmacokinetic parameters of some antiarrhythmic drugs in rabbits. Part I. Procainamide and its active metabolite-N-acetylprocainamide Acta Poloniae Pharmaceutica 52(2): 141-146
Yanaginuma, T. 1984: Clinical pharmacology for midwives. 3. Pregnancy and drugs. 3. Drugs with their risk superseding the benefits Josanpu Zasshi 38(6): 526-530
Nawada, T.; Tanaka, Y.; Hirai, S.; Hisatome, I.; Hasegawa, J.; Kotake, H.; Mashiba, H. 1994: Evaluation of negative inotropic and antiarrhythmic effects of class 1 antiarrhythmic drugs International Journal of Clinical Pharmacology and Therapeutics 32(7): 347-355
Dwenger, A. 1973: Chemistry, biochemistry and clinical pharmacology of digitalis glycosides. An overview Arzneimittel-Forschung 23(10): 1439-1446
Pfisterer, M. 1991: Negative inotropic effects of antiarrhythmic drugs: a clinical point of view Journal of Cardiovascular Pharmacology 17(Suppl 6): S44-S47
Mather, L.E.; Cousins, M.J. 1986: Pharmacology of opioids. Part 2. Clinical aspects Medical Journal of Australia 144(9): 475-481
Greco, F.A.; Hande, K.R. 1979: The clinical pharmacology and use of antineoplastic drugs Journal of the Tennessee Medical Association 72(1): 23-33
Cepeláková, H.; Petrlík, M.; Cepelák, V.; Roubal, Z. 1979: Clinical pharmacology of phlebotropic drugs Folia Haematologica 106(5-6): 714-723
Stanulović, M. 1989: Clinical pharmacology and the selection of drugs Medicinski Pregled 42(11-12): 391-394
Von Eickstedt, K.W. 1973: Experience with phase i of clinical pharmacology in the registration of drugs Arzneimittel-Forschung 23(11 Suppl): 1677-1678
Sharma, P.L. 1976: Clinical pharmacology of adrenergic beta-receptor blocking drugs Journal of the Association of Physicians of India 24(11): 729-735
Paris, W.; Callahan, M.B.; Pierson, M. 2010: Collaboration in academic and clinical research. Part 1: an overview Nephrology News and Issues 24(2): 41-42
Farnier, M. 1992: The "duration of administration" factor in studies of clinical pharmacology of hypolipemic drugs Archives des Maladies du Coeur et des Vaisseaux 85(Special Issue 2): 113-115